Genes contributing for nicotine dependence in humans

Information

  • Research Project
  • 7987207
  • ApplicationId
    7987207
  • Core Project Number
    R01DA017932
  • Full Project Number
    2R01DA017932-06A1
  • Serial Number
    17932
  • FOA Number
    PA-07-073
  • Sub Project Id
  • Project Start Date
    12/1/2003 - 21 years ago
  • Project End Date
    6/30/2016 - 8 years ago
  • Program Officer Name
    POLLOCK, JONATHAN D
  • Budget Start Date
    7/1/2011 - 13 years ago
  • Budget End Date
    6/30/2012 - 12 years ago
  • Fiscal Year
    2011
  • Support Year
    6
  • Suffix
    A1
  • Award Notice Date
    7/1/2011 - 13 years ago
Organizations

Genes contributing for nicotine dependence in humans

DESCRIPTION (provided by applicant): Addiction is a common and costly public health problem, and tobacco use is the leading cause of preventable deaths in the US, leading to an estimated 438,000 premature deaths per year. Nicotine is the substance in tobacco which is responsible for its addictive properties. The goal of our project is to identify gene variants that contribute to nicotine dependence, using both linkage and association studies of subjects from the Icelandic population. To study the genetics of nicotine dependence we have recruited over 5,000 smokers and re-phenotyped them using questionnaires and by interviews. To isolate susceptibility variants we have fine mapped regions linked to nicotine dependence through fully multipoint allele sharing linkage analysis that does not assume a particular inheritance model. Significant linkage peaks with high information content are ultrafine-mapped with hundreds of markers to define the underlying LD structure. The regions have been assessed in a case-control analysis to look for significant haplotype association to nicotine dependence. Genes found in Iceland using this approach are tested for their impact in outside populations already collected by scientific collaborators. The extensive phenotype data on the nicotine dependent patients and relatives will be used in more careful genotype-phenotype correlations as a way to understand their role in nicotine dependence and its co-morbidities.and treatment for this common and intractable problem, in humans representing most important risk factors for numerous diseases. The project is also conducting genome-wide association studies of smoking behavior in a large sample of smokers. The studies have already lead to the identification of three sequence variants correlating with ND. All variants also confer risk of lung cancer, underscoring the public health importance of understanding the genetics of nicotine dependence. In the continuation we plan to increase sample size for GWA studies in Iceland using long-range phasing approaches and joint analyses of large datasets. We will conduct pool sequencing for the discovery of less frequent variants that will subsequently be typed on a set of 2,500 samples that have been chosen to optimize their usefulness for propagating human sequence information into the rest of the Icelandic population using long-range-phasing approaches. The pools will be enriched in samples from carriers of variants detected in GWA studies, and high-risk haplotypes detected by long-range phasing analysis with a focus on linkage regions. In addition we will pay special attention to copy number variants in our approaches. To validate variants in identified in this manner in other populations we will rely on large sets of foreign ND and smoking behavior case-control samples, and a larger set of samples rich in information on both smoking-related diseases and psychiatric disorders. . PUBLIC HEALTH RELEVANCE: Addiction is a common and costly public health problem, and tobacco use is the leading cause of preventable deaths in the US. Understanding the genetic basis of nicotine dependence has enormous public health relevance, as the project has already demonstrated by identifying several genetic variants conferring risk of both nicotine dependence and lung cancer.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R01
  • Administering IC
    DA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    863787
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:863787\
  • Funding Mechanism
    Research Projects
  • Study Section
    GHD
  • Study Section Name
    Genetics of Health and Disease Study Section
  • Organization Name
    DECODE GENETICS, EHF
  • Organization Department
  • Organization DUNS
    552487134
  • Organization City
    REYKJAVIK
  • Organization State
  • Organization Country
    ICELAND
  • Organization Zip Code
    IS101
  • Organization District
    ICELAND